Proposed “reasonable pricing” march-in factor risks chilling innovation in attempt to leverage Bayh-Dole to lower drug prices
Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!
